InvestSMART

Invex Therapeutics Ltd (ASX:IXC)

ALERT: Price-sensitive ASX Announcement for IXC
Current share price for IXC : $0.115 -0.005 (-4.17%)+
Announcement
Release
23 Jul 2026 6:14PM
Price at Release
$0.120
Full Release
download
Summary
Invex Therapeutics Ltd, a biopharmaceutical company focused on neurological treatments, reported its quarterly financial results for the period ending June 30, 2026. The company ended the quarter with $4,016,000 in cash and cash equivalents, with operating cash outflows of $501,000, including $379,000 spent on research and development. This R&D investment was primarily for a preclinical research expansion with Tessara Therapeutics, testing Exenatide and other GLP-1 agonists in Alzheimer's models. Administrative costs were $135,000, linked to ASX compliance. Additionally, $54,000 was paid to related parties. The company's research aims to benchmark and explore combination regimens of Exenatide for improved Alzheimer's treatments.
Key Points
  • Invex Therapeutics Ltd is focused on the development and commercialization of Exenatide for neurological conditions related to raised intracranial pressure.
  • The company closed the quarter with cash and cash equivalents of $4,016,000, with operating cash outflows of $501,000.
  • Cash outflows included $379,000 for research and development, primarily related to the expansion of the preclinical research program with Tessara Therapeutics.
  • Administration and corporate costs amounted to $135,000, relating to ongoing compliance costs associated with being an ASX listed company.
  • The company announced an expanded preclinical research program with Tessara Therapeutics, evaluating Exenatide and other GLP-1 receptor agonists in Alzheimer's disease models.
  • The study aims to benchmark Exenatide against other GLP-1 agonists and assess combination regimens for potential therapeutic effects.
  • Aggregate payments to related parties and their associates for the quarter totaled $54,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.